Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Connection

William Robinson to Antineoplastic Combined Chemotherapy Protocols

This is a "connection" page, showing publications William Robinson has written about Antineoplastic Combined Chemotherapy Protocols.

 
Connection Strength
 
 
 
0.408
 
  1. Tobin RP, Jordan KR, Robinson WA, Davis D, Borges VF, Gonzalez R, Lewis KD, McCarter MD. Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. Int Immunopharmacol. 2018 Oct; 63:282-291.
    View in: PubMed
    Score: 0.089
  2. Gibbs P, Chen Q, Robinson WA. Effects of oncostatin M and tamoxifen on human melanoma cells. Melanoma Res. 1998 Jun; 8(3):221-6.
    View in: PubMed
    Score: 0.088
  3. Lien YH, Schr?ter GP, Weil R, Robinson WA. Complete remission and possible immune tolerance after multidrug combination chemotherapy for cyclosporine-related lymphoma in a renal transplant recipient with acute pancreatitis. Transplantation. 1991 Oct; 52(4):739-42.
    View in: PubMed
    Score: 0.055
  4. Lewis KD, Robinson WA, McCarter M, Pearlman N, O'Day SJ, Anderson C, Amatruda TT, Baron A, Zeng C, Becker M, Dollarhide S, Matijevich K, Gonzalez R. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol. 2006 Jul 01; 24(19):3157-63.
    View in: PubMed
    Score: 0.038
  5. Wettlaufer JN, Feiner AS, Robinson WA. Vincristine, cisplatin, and bleomycin with surgery in the management of advanced metastatic nonseminomatous testis tumors. Cancer. 1984 Jan 15; 53(2):203-9.
    View in: PubMed
    Score: 0.032
  6. Tobin RP, Cogswell DT, Cates VM, Davis DM, Borgers JSW, Van Gulick RJ, Katsnelson E, Couts KL, Jordan KR, Gao D, Davila E, Medina TM, Lewis KD, Gonzalez R, McFarland RW, Robinson WA, McCarter MD. Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma. Clin Cancer Res. 2023 04 03; 29(7):1209-1219.
    View in: PubMed
    Score: 0.031
  7. Mackin AG, Pecen PE, Dinsmore AL, Patnaik JL, Gonzalez R, Robinson WA, Palestine AG. Inflammatory side effects of BRAF and MEK inhibitors. Melanoma Res. 2019 10; 29(5):522-526.
    View in: PubMed
    Score: 0.024
  8. Feun LG, Robinson WA, Savaraj N, Gonzalez R, Liebmann A, Offenhauser K, Clendeninn NJ. Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma. Am J Clin Oncol. 1995 Dec; 18(6):488-90.
    View in: PubMed
    Score: 0.018
  9. Kirkwood JM, Ernstoff MS, Giuliano A, Gams R, Robinson WA, Costanzi J, Pouillart P, Speyer J, Grimm M, Spiegel R. Interferon alpha-2a and dacarbazine in melanoma. J Natl Cancer Inst. 1990 Jun 20; 82(12):1062-3.
    View in: PubMed
    Score: 0.013
  10. Mughal TI, Robinson WA, Thomas MR, Spiegel R. Role of recombinant interferon alpha 2 and cimetidine in patients with advanced malignant melanoma. J Cancer Res Clin Oncol. 1988; 114(1):108-9.
    View in: PubMed
    Score: 0.011
  11. Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, Wang HJ, Elashoff RM, Takeuchi H, Umetani N, Hoon DS. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol. 2005 Nov 01; 23(31):8057-64.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)